Journal article

Breast-Cancer Risk in Families with Mutations in PALB2

AC Antoniou, S Casadei, T Heikkinen, D Barrowdale, K Pylkaes, J Roberts, A Lee, D Subramanian, K De Leeneer, F Fostira, E Tomiak, SL Neuhausen, ZL Teo, S Khan, K Aittomaeki, JS Moilanen, C Turnbull, S Seal, A Mannermaa, A Kallioniemi Show all

New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2014


Awarded by European Union Seventh Framework Program, European Research Council

Awarded by Cancer Research UK

Awarded by National Institutes of Health

Awarded by Academy of Finland

Awarded by Fund for Scientific Research Flanders

Awarded by Ghent University

Awarded by National Cancer Institute

Awarded by Associazione Italiana per la Ricerca sul Cancro

Awarded by National Health and Medical Research Council Australia

Awarded by Victorian Cancer Agency

Funding Acknowledgements

Supported by grants from the European Union Seventh Framework Program (2007-2013)/European Research Council (310018, to Dr. Tischkowitz); Cancer Research UK (C12292/A11174, to Dr. Antoniou); the National Institutes of Health (R01CA175716, to Drs. Casadei and King; CA128978, CA116167, and CA116201, to Dr. Couch; and RFA CA-06-503, UM1 CA164920, RFA CA-06-503, U01 CA69467, U01 CA69417, U01 CA69398, U01 CA69631, U01 CA69446, and U01 CA69638, to Drs. Teo, Southey, Andrulis, Goldgar, and Hopper); the Academy of Finland (122715, to Dr. Winqvist; 250083, to Dr. Pylkas; Center of Excellence 251314, to Dr. Winqvist; and 266528, to Dr. Nevanlinna); the Finnish Cancer Foundation (to Dr. Winqvist and to Dr. Nevanlinna); the Sigrid Juselius Foundation (to Dr. Winqvist and to Dr. Nevanlinna); the University of Oulu, the University of Oulu Support Foundation and Biocenter Oulu, and the special Finnish Government EVO funds for Oulu University Hospital-based research activities (to Dr. Winqvist); the Helsinki University Central Hospital Research Fund and the Nordic Cancer Union (to Dr. Nevanlinna); the Fund for Scientific Research Flanders (G.A044.10, to Dr. Claes); Ghent University (BOF10/GOA/019, to Dr. De Leeneer); the European Union European Social Fund and Greek national funds through the operational program "Education and Lifelong Learning" of the National Strategic Reference Framework Research Funding Program, General Secretariat for Research and Technology (to Dr. Yannoukakos); Ohio State Comprehensive Cancer Center and the Stefanie Spielman Fund for Breast Cancer Research (to Dr. Toland); the National Cancer Institute (RC4A153828, to Dr. Weitzel; and CA083178, CA097397, CA114236, and CA129639, to Drs. Concannon and Bernstein); Susan G. Komen (to Drs. Domchek and Foulkes); Associazione Italiana per la Ricerca sul Cancro (IG 4017, to Drs. Manoukian and Peterlongo); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori (to Dr. Peterlongo); and National Health and Medical Research Council Australia (APP1029974), the Victorian Cancer Agency (CTTS07, EOI09_50), and the Victorian Breast Cancer Research Consortium (to Dr. Southey).